,PDB_ID,Title,Date,Entities,ChainID,Resolution,Identity,Coverage,NumGaps,GapLen,GapPos,NumLigs,NameLigs,Inhib,Inhib_mass
0,1aq1,human cyclin dependent kinase 2 complexed with the inhibitor staurosporine,1997-11-12,1,A,2.0,298.0,92.95302013422821,2.0,"[8, 13]","[[36, 43], [149, 161]]",1.0,"[""'STU'""]",STU,440.0
1,1b38,human cyclin-dependent kinase 2,1998-12-23,1,A,2.0,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",3.0,"[""'ACE'"", ""'ATP'"", ""'MG'""]",ATP,398.0
2,1b39,human cyclin-dependent kinase 2 phosphorylated on thr 160,1998-12-23,1,A,2.1,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",3.0,"[""'ACE'"", ""'ATP'"", ""'MG'""]",ATP,398.0
3,1buh,crystal structure of the human cdk2 kinase complex with cell cycle-regulatory protein ckshs1,1998-09-09,2,A,2.6,298.0,96.30872483221478,2.0,"[7, 4]","[[40, 46], [295, 298]]",0.0,[''],,
4,1ckp,human cyclin dependent kinase 2 complexed with the inhibitor purvalanol b,1999-01-13,1,A,2.05,298.0,93.62416107382549,2.0,"[8, 11]","[[36, 43], [153, 163]]",2.0,"[""'EDO'"", ""'PVB'""]",PVB,214.0
5,1di8,"the structure of cyclin-dependent kinase 2 (cdk2) in complex with 4-[3-hydroxyanilino]-6,7-dimethoxyquinazoline",2000-11-29,1,A,2.2,298.0,94.96644295302013,2.0,"[6, 9]","[[37, 42], [153, 161]]",1.0,"[""'DTQ'""]",DTQ,282.0
6,1dm2,human cyclin-dependent kinase 2 complexed with the inhibitor hymenialdisine,2000-05-31,1,A,2.1,298.0,91.9463087248322,2.0,"[9, 15]","[[36, 44], [149, 163]]",2.0,"[""'EDO'"", ""'HMD'""]",HMD,234.0
7,1e1v,human cyclin dependent kinase 2 complexed with the inhibitor nu2058,2001-05-10,1,A,1.95,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",2.0,"[""'ACE'"", ""'CMG'""]",CMG,230.0
8,1e1x,human cyclin dependent kinase 2 complexed with the inhibitor nu6027,2001-05-10,1,A,1.85,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",2.0,"[""'ACE'"", ""'NW1'""]",NW1,234.0
9,1e9h,thr 160 phosphorylated cdk2 - human cyclin a3 complex with the inhibitor indirubin-5-sulphonate bound,2001-10-11,2,A,2.5,295.0,99.32885906040268,1.0,[2],"[[296, 297]]",2.0,"[""'INR'"", ""'TPO'""]",INR,332.0
10,1f5q,crystal structure of murine gamma herpesvirus cyclin complexed to human cyclin dependent kinase 2,2000-12-27,2,A,2.5,298.0,99.32885906040268,1.0,[2],"[[10, 11]]",1.0,"[""'CL'""]",,
11,1fin,cyclin a-cyclin-dependent kinase 2 complex,1997-01-27,2,A,2.3,298.0,100.0,0.0,[],[],1.0,"[""'ATP'""]",ATP,398.0
12,1fq1,crystal structure of kinase associated phosphatase (kap) in complex with phospho-cdk2,2001-05-09,2,B,3.0,297.0,99.32885906040268,1.0,[2],"[[296, 297]]",3.0,"[""'ATP'"", ""'MG'"", ""'TPO'""]",ATP,398.0
13,1fvt,the structure of cyclin-dependent kinase 2 (cdk2) in complex with an oxindole inhibitor,2001-01-17,1,A,2.2,298.0,94.6308724832215,2.0,"[7, 9]","[[37, 43], [154, 162]]",1.0,"[""'106'""]",106,304.0
14,1fvv,the structure of cdk2/cyclin a in complex with an oxindole inhibitor,2001-01-17,2,A,2.8,298.0,100.0,0.0,[],[],1.0,"[""'107'""]",107,434.0
15,1g5s,crystal structure of human cyclin dependent kinase 2 (cdk2) in complex with the inhibitor h717,2001-11-02,1,A,2.61,298.0,92.28187919463085,2.0,"[9, 14]","[[37, 45], [149, 162]]",1.0,"[""'I17'""]",I17,374.0
16,1gih,human cyclin dependent kinase 2 complexed with the cdk4 inhibitor,2002-02-06,1,A,2.8,298.0,92.61744966442951,2.0,"[8, 14]","[[37, 44], [150, 163]]",1.0,"[""'1PU'""]",1PU,292.0
17,1gii,human cyclin dependent kinase 2 complexed with the cdk4 inhibitor,2002-02-06,1,A,2.0,295.0,93.62416107382549,2.0,"[8, 11]","[[36, 43], [153, 163]]",1.0,"[""'1PU'""]",1PU,292.0
18,1gij,human cyclin dependent kinase 2 complexed with the cdk4 inhibitor,2002-02-06,1,A,2.2,295.0,91.61073825503357,2.0,"[11, 14]","[[37, 47], [150, 163]]",1.0,"[""'2PU'""]",2PU,344.0
19,1gy3,"pcdk2/cyclin a in complex with mgadp, nitrate and peptide substrate",2002-04-29,3,A,2.7,297.0,99.32885906040268,1.0,[2],"[[296, 297]]",5.0,"[""'ATP'"", ""'GOL'"", ""'MG'"", ""'NO3'"", ""'TPO'""]",ATP,350.0
20,1gz8,human cyclin dependent kinase 2 complexed with the inhibitor 2-amino-6-(3'-methyl-2'-oxo)butoxypurine,2003-06-12,1,A,1.3,297.0,97.31543624161074,2.0,"[7, 1]","[[37, 43], [177, 177]]",3.0,"[""'ACE'"", ""'CSD'"", ""'MBP'""]",MBP,222.0
21,1h00,"cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor",2003-07-11,1,A,1.6,298.0,93.28859060402685,3.0,"[2, 8, 10]","[[13, 14], [36, 43], [152, 161]]",3.0,"[""'ACE'"", ""'FAP'"", ""'FCP'""]",FAP,354.0
22,1h01,"cdk2 in complex with a disubstituted 2, 4-bis anilino pyrimidine cdk4 inhibitor",2003-07-11,1,A,1.79,297.0,95.9731543624161,2.0,"[10, 2]","[[34, 43], [296, 297]]",4.0,"[""'FAL'"", ""'FBL'"", ""'GOL'"", ""'KCX'""]",FAL,354.0
23,1h07,"cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor",2003-07-11,1,A,1.85,298.0,95.63758389261746,3.0,"[7, 4, 2]","[[37, 43], [151, 154], [296, 297]]",3.0,"[""'ACE'"", ""'MFP'"", ""'MFQ'""]",MFP,404.0
24,1h08,"cdk2 in complex with a disubstituted 2, 4-bis anilino pyrimidine cdk4 inhibitor",2003-07-11,1,A,1.8,298.0,94.96644295302013,2.0,"[8, 7]","[[36, 43], [154, 160]]",4.0,"[""'ACE'"", ""'BWP'"", ""'BYP'"", ""'GOL'""]",BYP,354.0
25,1h0v,human cyclin dependent protein kinase 2 in complex with the inhibitor 2-amino-6-[(r)-pyrrolidino-5'-yl]methoxypurine,2003-06-27,1,A,1.9,298.0,96.64429530201343,2.0,"[7, 3]","[[37, 43], [159, 161]]",1.0,"[""'UN4'""]",UN4,236.0
26,1h0w,human cyclin dependent protein kinase 2 in complex with the inhibitor 2-amino-6-[cyclohex-3-enyl]methoxypurine,2003-06-27,1,A,2.1,298.0,94.96644295302013,2.0,"[7, 8]","[[37, 43], [156, 163]]",1.0,"[""'207'""]",207,228.0
27,1h1p,structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu2058,2002-09-19,2,A,2.1,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",2.0,"[""'CMG'"", ""'TPO'""]",CMG,230.0
28,1h1q,structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6094,2002-09-19,2,A,2.5,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",2.0,"[""'2A6'"", ""'TPO'""]",2A6,302.0
29,1h1r,structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6086,2002-09-19,2,A,2.0,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",2.0,"[""'6CP'"", ""'TPO'""]",6CP,302.0
30,1h1s,structure of human thr160-phospho cdk2/cyclin a complexed with the inhibitor nu6102,2002-09-19,2,A,2.0,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",2.0,"[""'4SP'"", ""'TPO'""]",4SP,380.0
31,1h24,cdk2/cyclina in complex with a 9 residue recruitment peptide from e2f,2003-02-01,3,A,2.5,297.0,98.65771812080536,1.0,[5],"[[295, 299]]",1.0,"[""'TPO'""]",,
32,1h25,cdk2/cyclin a in complex with an 11-residue recruitment peptide from retinoblastoma-associated protein,2003-02-01,3,A,2.5,297.0,98.65771812080536,1.0,[5],"[[295, 299]]",1.0,"[""'TPO'""]",,
33,1h26,cdk2/cyclina in complex with an 11-residue recruitment peptide from p53,2003-02-01,3,A,2.24,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",1.0,"[""'TPO'""]",,
34,1h27,cdk2/cyclina in complex with an 11-residue recruitment peptide from p27,2003-02-01,3,A,2.2,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",1.0,"[""'TPO'""]",,
35,1h28,cdk2/cyclina in complex with an 11-residue recruitment peptide from p107,2003-02-01,3,A,2.8,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",1.0,"[""'TPO'""]",,
36,1hck,human cyclin-dependent kinase 2,1996-12-07,1,A,1.9,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'ATP'"", ""'MG'""]",ATP,398.0
37,1hcl,human cyclin-dependent kinase 2,1996-12-07,1,A,1.8,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",0.0,[''],,
38,1jst,phosphorylated cyclin-dependent kinase-2 bound to cyclin a,1997-01-11,2,A,2.6,297.0,100.0,0.0,[],[],3.0,"[""'ATP'"", ""'MN'"", ""'TPO'""]",ATP,398.0
39,1jsv,the structure of cyclin-dependent kinase 2 (cdk2) in complex with 4-[(6-amino-4-pyrimidinyl)amino]benzenesulfonamide,2001-08-29,1,A,1.96,298.0,96.30872483221478,1.0,[11],"[[36, 46]]",1.0,"[""'U55'""]",U55,254.0
40,1jvp,crystal structure of human cdk2 (unphosphorylated) in complex with pkf049-365,2001-12-21,1,P,1.53,298.0,89.93288590604027,4.0,"[7, 5, 14, 4]","[[37, 43], [81, 85], [145, 158], [252, 255]]",1.0,"[""'LIG'""]",,
41,1ke5,"cdk2 complexed with n-methyl-4-{[(2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl]amino}benzenesulfonamide",2002-05-14,1,A,2.2,298.0,94.29530201342286,2.0,"[7, 10]","[[37, 43], [153, 162]]",1.0,"[""'LS1'""]",LS1,314.0
42,1ke6,"cyclin-dependent kinase 2 (cdk2) complexed with n-methyl-{4-[2-(7-oxo-6,7-dihydro-8h-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide",2002-05-14,1,A,2.0,298.0,93.95973154362416,2.0,"[7, 11]","[[37, 43], [153, 163]]",1.0,"[""'LS2'""]",LS2,386.0
43,1ke7,"cyclin-dependent kinase 2 (cdk2) complexed with 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2h-indol-2-one",2002-05-14,1,A,2.0,298.0,94.29530201342286,2.0,"[7, 10]","[[37, 43], [153, 162]]",1.0,"[""'LS3'""]",LS3,378.0
44,1ke8,"cyclin-dependent kinase 2 (cdk2) complexed with 4-{[(2-oxo-1,2-dihydro-3h-indol-3-ylidene)methyl]amino}-n-(1,3-thiazol-2-yl)benzenesulfonamide",2002-05-14,1,A,2.0,298.0,94.6308724832215,2.0,"[7, 9]","[[37, 43], [154, 162]]",1.0,"[""'LS4'""]",LS4,384.0
45,1ke9,"cyclin-dependent kinase 2 (cdk2) complexed with 3-{[4-({[amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1h-indole",2002-05-14,1,A,2.0,298.0,94.29530201342286,2.0,"[7, 10]","[[37, 43], [153, 162]]",1.0,"[""'LS5'""]",LS5,342.0
46,1ogu,structure of human thr160-phospho cdk2/cyclin a complexed with a 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitor,2003-09-02,2,A,2.6,297.0,99.66442953020132,2.0,"[3, 1]","[[41, 43], [301, 301]]",3.0,"[""'SGM'"", ""'ST8'"", ""'TPO'""]",ST8,348.0
47,1oi9,structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor,2004-07-13,2,A,2.1,297.0,99.32885906040268,2.0,"[1, 2]","[[39, 39], [297, 298]]",4.0,"[""'MG'"", ""'N20'"", ""'SGM'"", ""'TPO'""]",N20,318.0
48,1oiq,imidazopyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation,2003-09-04,1,A,2.31,298.0,88.59060402684564,4.0,"[4, 11, 3, 16]","[[12, 15], [36, 46], [73, 75], [149, 164]]",2.0,"[""'ACE'"", ""'HDU'""]",HDU,254.0
49,1oir,imidazopyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation,2003-09-04,1,A,1.91,297.0,95.9731543624161,2.0,"[10, 2]","[[34, 43], [296, 297]]",3.0,"[""'ACE'"", ""'HDY'"", ""'KCX'""]",HDY,392.0
50,1oit,imidazopyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation,2003-09-04,1,A,1.6,297.0,91.61073825503357,3.0,"[2, 12, 11]","[[1, 2], [34, 45], [152, 162]]",2.0,"[""'ACE'"", ""'HDT'""]",HDT,352.0
51,1oiu,structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor,2004-07-13,2,A,2.0,297.0,99.66442953020132,2.0,"[3, 1]","[[41, 43], [301, 301]]",4.0,"[""'MG'"", ""'N76'"", ""'SGM'"", ""'TPO'""]",N76,380.0
52,1oiy,structure of human thr160-phospho cdk2/cyclin a complexed with a 6-cyclohexylmethyloxy-2-anilino-purine inhibitor,2004-07-13,2,A,2.4,297.0,98.65771812080536,2.0,"[3, 2]","[[39, 41], [297, 298]]",4.0,"[""'MG'"", ""'N41'"", ""'SGM'"", ""'TPO'""]",N41,344.0
53,1okv,cyclin a binding groove inhibitor h-arg-arg-leu-ile-phe-nh2,2003-12-11,3,A,2.4,298.0,98.99328859060402,1.0,[3],"[[296, 298]]",1.0,"[""'NH2'""]",,
54,1okw,cyclin a binding groove inhibitor ac-arg-arg-leu-asn-(m-cl-phe)-nh2,2003-12-11,3,A,2.5,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",3.0,"[""'ACE'"", ""'FCL'"", ""'NH2'""]",,
55,1ol1,cyclin a binding groove inhibitor h-cit-cit-leu-ile-(p-f-phe)-nh2,2003-12-11,3,A,2.9,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",3.0,"[""'CIR'"", ""'NH2'"", ""'PFF'""]",,
56,1ol2,cyclin a binding groove inhibitor h-arg-arg-leu-asn-(p-f-phe)-nh2,2003-12-11,3,A,2.6,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",2.0,"[""'NH2'"", ""'PFF'""]",,
57,1p2a,the structure of cyclin dependent kinase 2 (ckd2) with a trisubstituted naphthostyril inhibitor,2003-07-15,1,A,2.5,298.0,90.93959731543623,3.0,"[3, 10, 14]","[[13, 15], [38, 47], [150, 163]]",1.0,"[""'5BN'""]",5BN,276.0
58,1p5e,"the structure of phospho-cdk2/cyclin a in complex with the inhibitor 4,5,6,7-tetrabromobenzotriazole (tbs)",2003-07-01,2,A,2.22,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",2.0,"[""'TBS'"", ""'TPO'""]",TBS,114.0
59,1pf8,crystal structure of human cyclin-dependent kinase 2 complexed with a nucleoside inhibitor,2003-12-23,1,A,2.51,297.0,100.0,0.0,[],[],1.0,"[""'SU9'""]",SU9,230.0
60,1pkd,the crystal structure of ucn-01 in complex with phospho-cdk2/cyclin a,2003-06-24,2,A,2.3,295.0,99.66442953020132,1.0,[2],"[[297, 298]]",2.0,"[""'TPO'"", ""'UCN'""]",UCN,456.0
61,1pw2,apo structure of human cyclin-dependent kinase 2,2003-12-09,1,A,1.95,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",0.0,[''],,
62,1pxi,"human cyclin dependent kinase 2 complexed with the inhibitor 4-(2,5-dichloro-thiophen-3-yl)-pyrimidin-2-ylamine",2003-12-09,1,A,1.95,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'CK1'""]",CK1,170.0
63,1pxj,"human cyclin dependent kinase 2 complexed with the inhibitor 4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamine",2003-12-09,1,A,2.3,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'CK2'""]",CK2,196.0
64,1pxk,"human cyclin dependent kinase 2 complexed with the inhibitor n-[4-(2,4-dimethyl-thiazol-5-yl)pyrimidin-2-yl]-n'-hydroxyiminoformamide",2003-12-09,1,A,2.8,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",1.0,"[""'CK3'""]",CK3,238.0
65,1pxl,"human cyclin dependent kinase 2 complexed with the inhibitor [4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-trifluoromethyl-phenyl)-amine",2003-12-09,1,A,2.5,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",1.0,"[""'CK4'""]",CK4,280.0
66,1pxm,"human cyclin dependent kinase 2 complexed with the inhibitor 3-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol",2004-04-13,1,A,2.53,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",1.0,"[""'CK5'""]",CK5,284.0
67,1pxn,human cyclin dependent kinase 2 complexed with the inhibitor 4-[4-(4-methyl-2-methylamino-thiazol-5-yl)-pyrimidin-2-ylamino]-phenol,2004-04-13,1,A,2.5,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'CK6'""]",CK6,298.0
68,1pxo,human cyclin dependent kinase 2 complexed with the inhibitor [4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(3-nitro-phenyl)-amine,2004-04-13,1,A,1.96,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'CK7'""]",CK7,198.0
69,1pxp,"human cyclin dependent kinase 2 complexed with the inhibitor n-[4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-n',n'-dimethyl-benzene-1,4-diamine",2004-04-13,1,A,2.3,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'CK8'""]",CK8,306.0
70,1pye,crystal structure of cdk2 with inhibitor,2004-07-13,1,A,2.0,298.0,89.26174496644295,4.0,"[3, 11, 2, 16]","[[13, 15], [36, 46], [74, 75], [147, 162]]",1.0,"[""'PM1'""]",PM1,326.0
71,1qmz,phosphorylated cdk2-cyclyin a-substrate peptide complex,1999-12-14,3,A,2.2,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",3.0,"[""'ATP'"", ""'MG'"", ""'TPO'""]",ATP,398.0
72,1r78,cdk2 complex with a 4-alkynyl oxindole inhibitor,2004-01-20,1,A,2.0,298.0,91.61073825503357,2.0,"[9, 16]","[[38, 46], [148, 163]]",1.0,"[""'FMD'""]",FMD,346.0
73,1urc,cyclin a binding groove inhibitor ace-arg-lys-leu-phe-gly,2003-10-31,3,A,2.6,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",1.0,"[""'ACE'""]",,
74,1urw,"cdk2 in complex with an imidazo[1,2-b]pyridazine",2004-04-23,1,A,1.6,298.0,91.9463087248322,3.0,"[2, 11, 11]","[[13, 14], [36, 46], [152, 162]]",2.0,"[""'ACE'"", ""'I1P'""]",I1P,428.0
75,1v1k,"cdk2 in complex with a disubstituted 4, 6-bis anilino pyrimidine cdk4 inhibitor",2004-05-04,1,A,2.31,298.0,92.95302013422821,2.0,"[9, 12]","[[38, 46], [151, 162]]",2.0,"[""'3FP'"", ""'ACE'""]",3FP,366.0
76,1vyw,structure of cdk2/cyclin a with pnu-292137,2004-06-10,2,A,2.3,298.0,101.34228187919464,0.0,[],[],2.0,"[""'292'"", ""'SO4'""]",292,274.0
77,1vyz,structure of cdk2 complexed with pnu-181227,2004-06-17,1,A,2.21,298.0,93.62416107382549,2.0,"[11, 8]","[[36, 46], [154, 161]]",1.0,"[""'N5B'""]",N5B,214.0
78,1w0x,crystal structure of human cdk2 in complex with the inhibitor olomoucine.,2005-01-14,1,C,2.2,298.0,93.95973154362416,2.0,"[7, 11]","[[37, 43], [153, 163]]",1.0,"[""'OLO'""]",OLO,283.0
79,1w8c,co-crystal structure of 6-cyclohexylmethoxy-8-isopropyl-9h-purin-2- ylamine and monomeric cdk2,2006-08-30,1,A,2.05,297.0,97.31543624161074,2.0,"[7, 1]","[[37, 43], [177, 177]]",3.0,"[""'ACE'"", ""'CSD'"", ""'N69'""]",N69,266.0
80,1w98,the structural basis of cdk2 activation by cyclin e,2005-02-02,2,A,2.15,296.0,100.0,1.0,[1],"[[299, 299]]",1.0,"[""'TPO'""]",,
81,1wcc,screening for fragment binding by x-ray crystallography,2005-01-27,1,A,2.2,298.0,94.96644295302013,2.0,"[4, 11]","[[37, 40], [153, 163]]",1.0,"[""'CIG'""]",CIG,90.0
82,1y8y,"crystal structure of human cdk2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitor",2005-02-08,1,A,2.0,298.0,97.98657718120806,1.0,[6],"[[38, 43]]",1.0,"[""'CT7'""]",CT7,276.0
83,1y91,"crystal structure of human cdk2 complexed with a pyrazolo[1,5-a]pyrimidine inhibitor",2005-02-08,1,A,2.15,298.0,95.9731543624161,2.0,"[7, 5]","[[38, 44], [154, 158]]",1.0,"[""'CT9'""]",CT9,438.0
84,1ykr,crystal structure of cdk2 with an aminoimidazo pyridine inhibitor,2006-01-24,1,A,1.8,298.0,100.0,0.0,[],[],1.0,"[""'628'""]",628,376.0
85,2a0c,"human cdk2 in complex with olomoucine ii, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor",2006-01-24,1,X,1.95,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'CK9'""]",CK9,344.0
86,2a4l,human cyclin-dependent kinase 2 in complex with roscovitine,2006-10-03,1,A,2.4,298.0,95.9731543624161,1.0,[12],"[[36, 47]]",1.0,"[""'RRC'""]",RRC,328.0
87,2b52,human cyclin dependent kinase 2 (cdk2) complexed with dph-042562,2005-10-11,1,A,1.88,298.0,94.96644295302013,2.0,"[4, 11]","[[37, 40], [150, 160]]",1.0,"[""'D42'""]",D42,414.0
88,2b53,human cyclin dependent kinase 2 (cdk2) complexed with din-234325,2005-10-11,1,A,2.0,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'D23'""]",D23,284.0
89,2b54,human cyclin dependent kinase 2 (ckd2)complexed with din-232305,2005-10-11,1,A,1.85,298.0,100.0,0.0,[],[],1.0,"[""'D05'""]",D05,344.0
90,2b55,human cyclin dependent kinase 2 (cdk2) complexed with indenopyraxole din-101312,2005-10-11,1,A,1.85,298.0,92.61744966442951,2.0,"[7, 15]","[[36, 42], [148, 162]]",1.0,"[""'D31'""]",D31,390.0
91,2bhe,human cyclin dependent protein kinase 2 in complex with the inhibitor 5-bromo-indirubine,2005-03-09,1,A,1.9,298.0,91.9463087248322,2.0,"[9, 15]","[[36, 44], [149, 163]]",1.0,"[""'BRY'""]",BRY,252.0
92,2bhh,human cyclin dependent protein kinase 2 in complex with the inhibitor 4-hydroxypiperindinesulfonyl-indirubine,2005-03-09,1,A,2.6,298.0,91.9463087248322,2.0,"[9, 15]","[[36, 44], [149, 163]]",1.0,"[""'RYU'""]",RYU,418.0
93,2bkz,structure of cdk2-cyclin a with pha-404611,2006-03-08,2,A,2.6,298.0,101.34228187919464,0.0,[],[],2.0,"[""'SBC'"", ""'SO4'""]",SBC,344.0
94,2bpm,structure of cdk2-cyclin a with pha-630529,2005-12-08,2,A,2.4,298.0,101.34228187919464,0.0,[],[],2.0,"[""'529'"", ""'SO4'""]",529,318.0
95,2btr,structure of cdk2 complexed with pnu-198873,2005-11-09,1,A,1.85,298.0,92.28187919463085,2.0,"[11, 12]","[[36, 46], [150, 161]]",1.0,"[""'U73'""]",U73,246.0
96,2bts,structure of cdk2 complexed with pnu-230032,2005-11-09,1,A,1.99,298.0,91.9463087248322,2.0,"[9, 15]","[[37, 45], [149, 163]]",1.0,"[""'U32'""]",U32,282.0
97,2c4g,structure of cdk2-cyclin a with pha-533514,2005-11-23,2,A,2.7,298.0,101.00671140939596,1.0,[1],"[[302, 302]]",2.0,"[""'514'"", ""'SO4'""]",514,256.0
98,2c5n,differential binding of inhibitors to active and inactive cdk2 provides insights for drug design,2006-03-01,2,A,2.1,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",1.0,"[""'CK8'""]",CK8,306.0
99,2c5o,differential binding of inhibitors to active and inactive cdk2 provides insights for drug design,2006-03-01,2,A,2.1,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",1.0,"[""'CK2'""]",CK2,196.0
100,2c5v,differential binding of inhibitors to active and inactive cdk2 provides insights for drug design,2006-03-01,3,A,2.9,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",4.0,"[""'ABA'"", ""'CK4'"", ""'NH2'"", ""'PFF'""]",CK4,280.0
101,2c5x,differential binding of inhibitors to active and inactive cdk2 provides insights for drug design,2006-03-01,2,A,2.9,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",1.0,"[""'MTW'""]",MTW,358.0
102,2c5y,differential binding of inhibitors to active and inactive cdk2 provides insights for drug design,2006-03-01,1,A,2.25,298.0,97.31543624161074,2.0,"[7, 1]","[[36, 42], [298, 298]]",1.0,"[""'MTW'""]",MTW,358.0
103,2c68,crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor,2005-12-07,1,A,1.95,298.0,97.31543624161074,2.0,"[6, 2]","[[38, 43], [296, 297]]",1.0,"[""'CT6'""]",CT6,286.0
104,2c69,crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor,2005-12-07,1,A,2.1,298.0,97.98657718120806,1.0,[6],"[[38, 43]]",1.0,"[""'CT8'""]",CT8,288.0
105,2c6i,crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor,2005-12-07,1,A,1.8,298.0,97.98657718120806,1.0,[6],"[[38, 43]]",1.0,"[""'DT1'""]",DT1,380.0
106,2c6k,crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor,2005-12-07,1,A,1.9,298.0,97.98657718120806,1.0,[6],"[[38, 43]]",1.0,"[""'DT2'""]",DT2,366.0
107,2c6l,crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor,2005-12-07,1,A,2.3,298.0,97.6510067114094,1.0,[7],"[[37, 43]]",1.0,"[""'DT4'""]",DT4,380.0
108,2c6m,crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor,2005-12-07,1,A,1.9,298.0,97.31543624161074,2.0,"[6, 2]","[[38, 43], [296, 297]]",1.0,"[""'DT5'""]",DT5,368.0
109,2c6o,crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor,2005-12-07,1,A,2.1,298.0,97.31543624161074,2.0,"[6, 2]","[[38, 43], [296, 297]]",1.0,"[""'4SP'""]",4SP,380.0
110,2c6t,crystal structure of the human cdk2 complexed with the triazolopyrimidine inhibitor,2005-12-07,2,A,2.61,297.0,99.32885906040268,1.0,[2],"[[296, 297]]",2.0,"[""'DT5'"", ""'TPO'""]",DT5,368.0
111,2cch,the crystal structure of cdk2 cyclin a in complex with a substrate peptide derived from cdc modified with a gamma-linked atp analogue,2006-05-03,3,A,1.7,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",4.0,"[""'ATP'"", ""'GOL'"", ""'SO4'"", ""'TPO'""]",ATP,398.0
112,2cci,crystal structure of phospho-cdk2 cyclin a in complex with a peptide containing both the substrate and recruitment sites of cdc6,2006-05-03,3,A,2.7,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",3.0,"[""'ATP'"", ""'MG'"", ""'TPO'""]",ATP,398.0
113,2cjm,mechanism of cdk inhibition by active site phosphorylation: cdk2 y15p t160p in complex with cyclin a structure,2006-04-24,2,A,2.3,296.0,96.30872483221478,2.0,"[5, 6]","[[37, 41], [293, 298]]",4.0,"[""'ATP'"", ""'MG'"", ""'PTR'"", ""'TPO'""]",ATP,398.0
114,2clx,"4-arylazo-3,5-diamino-1h-pyrazole cdk inhibitors: sar study, crystal structure in complex with cdk2, selectivity, and cellular effects",2006-11-01,1,A,1.8,298.0,98.3221476510067,1.0,[5],"[[38, 42]]",1.0,"[""'F18'""]",F18,208.0
115,2ds1,human cyclin dependent kinase 2 complexed with the cdk4 inhibitor,2007-06-19,1,A,2.0,295.0,97.31543624161074,1.0,[8],"[[36, 43]]",1.0,"[""'1CD'""]",1CD,382.0
116,2duv,structure of cdk2 with a 3-hydroxychromones,2007-01-27,1,A,2.2,298.0,91.27516778523491,2.0,"[13, 13]","[[36, 48], [151, 163]]",1.0,"[""'371'""]",371,386.0
117,2exm,human cdk2 in complex with isopentenyladenine,2005-12-27,1,A,1.8,298.0,100.0,0.0,[],[],1.0,"[""'ZIP'""]",ZIP,190.0
118,2fvd,cyclin dependent kinase 2 (cdk2) with diaminopyrimidine inhibitor,2006-10-10,1,A,1.85,298.0,95.30201342281879,2.0,"[12, 2]","[[38, 49], [149, 150]]",1.0,"[""'LIA'""]",LIA,382.0
119,2g9x,structure of thr 160 phosphorylated cdk2/cyclin a in complex with the inhibitor nu6271,2006-05-23,2,A,2.5,297.0,100.33557046979868,0.0,[],[],2.0,"[""'NU5'"", ""'TPO'""]",NU5,456.0
120,2i40,cdk2/cyclin a complexed with a thiophene carboxamide inhibitor,2006-10-10,2,A,2.8,298.0,97.6510067114094,3.0,"[3, 3, 1]","[[38, 40], [160, 162], [298, 298]]",1.0,"[""'BLZ'""]",BLZ,402.0
121,2iw6,structure of human thr160-phospho cdk2-cyclin a complexed with a bisanilinopyrimidine inhibitor,2006-09-06,2,A,2.3,296.0,98.3221476510067,2.0,"[3, 3]","[[39, 41], [297, 299]]",4.0,"[""'MG'"", ""'QQ2'"", ""'SGM'"", ""'TPO'""]",QQ2,404.0
122,2iw8,structure of human thr160-phospho cdk2-cyclin a f82h-l83v-h84d mutant with an o6-cyclohexylmethylguanine inhibitor,2006-09-06,2,A,2.3,294.0,100.0,1.0,[1],"[[299, 299]]",3.0,"[""'4SP'"", ""'SGM'"", ""'TPO'""]",4SP,380.0
123,2iw9,structure of human thr160-phospho cdk2-cyclin a complexed with a bisanilinopyrimidine inhibitor,2006-09-06,2,A,2.0,296.0,98.65771812080536,2.0,"[4, 1]","[[39, 42], [299, 299]]",4.0,"[""'4SP'"", ""'MG'"", ""'SGM'"", ""'TPO'""]",4SP,380.0
124,2j9m,crystal structure of cdk2 in complex with macrocyclic aminopyrimidine,2007-11-06,1,A,2.5,298.0,92.28187919463085,2.0,"[8, 15]","[[37, 44], [149, 163]]",1.0,"[""'PY8'""]",PY8,290.0
125,2jgz,crystal structure of phospho-cdk2 in complex with cyclin b,2007-05-22,2,A,2.9,287.0,96.97986577181207,1.0,[10],"[[290, 299]]",1.0,"[""'TPO'""]",,
126,2r3f,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.5,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",2.0,"[""'ACE'"", ""'SC8'""]",SC8,286.0
127,2r3g,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.55,298.0,96.30872483221478,1.0,[11],"[[36, 46]]",2.0,"[""'ACE'"", ""'SC9'""]",SC9,286.0
128,2r3h,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.5,298.0,96.97986577181207,1.0,[9],"[[36, 44]]",2.0,"[""'ACE'"", ""'SCE'""]",SCE,226.0
129,2r3i,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.28,297.0,96.97986577181207,2.0,"[8, 1]","[[36, 43], [177, 177]]",3.0,"[""'ACE'"", ""'CSD'"", ""'SCF'""]",SCF,286.0
130,2r3j,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.65,297.0,93.28859060402685,3.0,"[8, 11, 1]","[[36, 43], [151, 161], [177, 177]]",3.0,"[""'ACE'"", ""'CSD'"", ""'SCJ'""]",SCJ,286.0
131,2r3k,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.7,297.0,92.95302013422821,3.0,"[8, 12, 1]","[[36, 43], [151, 162], [177, 177]]",3.0,"[""'ACE'"", ""'CSD'"", ""'SCQ'""]",SCQ,286.0
132,2r3l,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.65,297.0,92.28187919463085,3.0,"[7, 15, 1]","[[37, 43], [150, 164], [177, 177]]",3.0,"[""'ACE'"", ""'CSD'"", ""'SCW'""]",SCW,286.0
133,2r3m,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.7,297.0,93.28859060402685,3.0,"[8, 11, 1]","[[36, 43], [151, 161], [177, 177]]",3.0,"[""'ACE'"", ""'CSD'"", ""'SCX'""]",SCX,326.0
134,2r3n,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.63,297.0,92.28187919463085,3.0,"[8, 14, 1]","[[36, 43], [149, 162], [177, 177]]",3.0,"[""'ACE'"", ""'CSD'"", ""'SCZ'""]",SCZ,322.0
135,2r3o,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.8,297.0,96.97986577181207,2.0,"[8, 1]","[[36, 43], [177, 177]]",3.0,"[""'2SC'"", ""'ACE'"", ""'CSD'""]",2SC,314.0
136,2r3p,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.66,297.0,96.97986577181207,2.0,"[8, 1]","[[36, 43], [177, 177]]",3.0,"[""'3SC'"", ""'ACE'"", ""'CSD'""]",3SC,344.0
137,2r3q,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.35,297.0,95.9731543624161,2.0,"[11, 1]","[[36, 46], [177, 177]]",3.0,"[""'5SC'"", ""'ACE'"", ""'CSD'""]",5SC,314.0
138,2r3r,crystal structure of cyclin-dependent kinase 2 with inhibitor,2008-01-22,1,A,1.47,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",2.0,"[""'6SC'"", ""'ACE'""]",6SC,286.0
139,2r64,crystal structure of a 3-aminoindazole compound with cdk2,2008-09-09,1,A,2.3,298.0,93.62416107382549,2.0,"[8, 11]","[[36, 43], [153, 163]]",1.0,"[""'740'""]",740,426.0
140,2uue,replace: a strategy for iterative design of cyclin binding groove inhibitors,2007-03-27,3,A,2.06,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",4.0,"[""'GVC'"", ""'MTZ'"", ""'NH2'"", ""'PFF'""]",MTZ,348.0
141,2uzb,crystal structure of human cdk2 complexed with a thiazolidinone inhibitor,2007-06-26,2,A,2.7,297.0,99.32885906040268,1.0,[2],"[[296, 297]]",2.0,"[""'C75'"", ""'TPO'""]",C75,350.0
142,2uzd,crystal structure of human cdk2 complexed with a thiazolidinone inhibitor,2007-06-26,2,A,2.72,297.0,99.32885906040268,1.0,[2],"[[296, 297]]",2.0,"[""'C85'"", ""'TPO'""]",C85,338.0
143,2uze,crystal structure of human cdk2 complexed with a thiazolidinone inhibitor,2007-06-26,2,A,2.4,297.0,99.32885906040268,1.0,[2],"[[296, 297]]",2.0,"[""'C95'"", ""'TPO'""]",C95,304.0
144,2uzl,crystal structure of human cdk2 complexed with a thiazolidinone inhibitor,2007-06-26,2,A,2.4,297.0,99.32885906040268,1.0,[2],"[[296, 297]]",2.0,"[""'C94'"", ""'TPO'""]",C94,350.0
145,2uzn,crystal structure of human cdk2 complexed with a thiazolidinone inhibitor,2007-06-26,1,A,2.3,298.0,93.62416107382549,2.0,"[9, 10]","[[36, 44], [153, 162]]",1.0,"[""'C96'""]",C96,350.0
146,2uzo,crystal structure of human cdk2 complexed with a thiazolidinone inhibitor,2007-06-26,1,A,2.3,298.0,97.31543624161074,2.0,"[6, 2]","[[38, 43], [296, 297]]",1.0,"[""'C62'""]",C62,340.0
147,2v0d,crystal structure of human cdk2 complexed with a thiazolidinone inhibitor,2007-06-26,1,A,2.2,298.0,97.98657718120806,1.0,[6],"[[38, 43]]",2.0,"[""'C53'"", ""'CL'""]",C53,198.0
148,2v22,replace: a strategy for iterative design of cyclin binding groove inhibitors,2008-01-29,2,A,2.6,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",1.0,"[""'C35'""]",,
149,2vta,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design.",2008-08-05,1,A,2.0,298.0,93.28859060402685,2.0,"[9, 11]","[[37, 45], [153, 163]]",2.0,"[""'GOL'"", ""'LZ1'""]",LZ1,112.0
150,2vth,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h-pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design",2008-08-05,1,A,1.9,298.0,93.28859060402685,2.0,"[9, 11]","[[37, 45], [153, 163]]",2.0,"[""'GOL'"", ""'LZ2'""]",LZ2,214.0
151,2vti,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design.",2008-08-05,1,A,2.0,298.0,93.95973154362416,2.0,"[8, 10]","[[36, 43], [153, 162]]",1.0,"[""'LZ3'""]",LZ3,304.0
152,2vtj,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design",2008-08-05,1,A,2.2,298.0,92.61744966442951,2.0,"[9, 13]","[[37, 45], [151, 163]]",2.0,"[""'GOL'"", ""'LZ4'""]",LZ4,240.0
153,2vtl,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design",2008-08-05,1,A,2.0,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",1.0,"[""'LZ5'""]",LZ5,178.0
154,2vtm,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design.",2008-08-05,1,A,2.25,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",1.0,"[""'LZM'""]",LZM,140.0
155,2vtn,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design.",2008-08-05,1,A,2.2,298.0,91.9463087248322,2.0,"[8, 16]","[[37, 44], [148, 163]]",1.0,"[""'LZ7'""]",LZ7,232.0
156,2vto,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design.",2008-08-05,1,A,2.19,298.0,94.96644295302013,2.0,"[7, 8]","[[37, 43], [153, 160]]",1.0,"[""'LZ8'""]",LZ8,292.0
157,2vtp,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design.",2008-08-05,1,A,2.15,298.0,94.29530201342286,2.0,"[8, 9]","[[36, 43], [153, 161]]",1.0,"[""'LZ9'""]",LZ9,292.0
158,2vtq,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design.",2008-08-05,1,A,1.9,298.0,91.9463087248322,2.0,"[9, 15]","[[37, 45], [148, 162]]",1.0,"[""'LZA'""]",LZA,294.0
159,2vtr,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design",2008-08-05,1,A,1.89,298.0,97.31543624161074,1.0,[8],"[[37, 44]]",1.0,"[""'LZB'""]",LZB,190.0
160,2vts,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design.",2008-08-05,1,A,1.9,298.0,94.6308724832215,2.0,"[8, 8]","[[37, 44], [153, 160]]",1.0,"[""'LZC'""]",LZC,290.0
161,2vtt,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design.",2008-08-05,1,A,1.68,298.0,91.27516778523491,2.0,"[11, 15]","[[36, 46], [149, 163]]",1.0,"[""'LZD'""]",LZD,294.0
162,2vu3,"identification of n-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1h- pyrazole-3-carboxamide (at7519), a novel cyclin dependent kinase inhibitor using fragment-based x-ray crystallography and structure based drug design.",2008-08-05,1,A,1.85,298.0,95.63758389261746,2.0,"[9, 4]","[[38, 46], [148, 151]]",1.0,"[""'LZE'""]",LZE,294.0
163,2vv9,cdk2 in complex with an imidazole piperazine,2008-08-05,1,A,1.9,298.0,93.62416107382549,2.0,"[6, 13]","[[38, 43], [150, 162]]",2.0,"[""'ACE'"", ""'IM9'""]",IM9,406.0
164,2w05,"structure of cdk2 in complex with an imidazolyl pyrimidine, compound 5b",2008-10-14,1,A,1.9,298.0,92.61744966442951,2.0,"[9, 13]","[[37, 45], [149, 161]]",1.0,"[""'FRT'""]",FRT,404.0
165,2w06,"structure of cdk2 in complex with an imidazolyl pyrimidine, compound 5c",2008-09-23,1,A,2.04,298.0,94.6308724832215,2.0,"[7, 9]","[[37, 43], [153, 161]]",2.0,"[""'ACE'"", ""'FRV'""]",FRV,364.0
166,2w17,"cdk2 in complex with the imidazole pyrimidine amide, compound (s)-8b",2008-11-04,1,A,2.15,298.0,93.28859060402685,4.0,"[1, 5, 1, 13]","[[13, 13], [39, 43], [74, 74], [150, 162]]",3.0,"[""'ACE'"", ""'ACT'"", ""'I19'""]",I19,402.0
167,2w1h,"fragment-based discovery of the pyrazol-4-yl urea (at9283), a multi- targeted kinase inhibitor with potent aurora kinase activity",2009-01-27,1,A,2.15,298.0,94.96644295302013,2.0,"[4, 11]","[[37, 40], [153, 163]]",1.0,"[""'L0F'""]",L0F,290.0
168,2wev,"truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design",2009-06-09,3,A,2.3,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",5.0,"[""'ACE'"", ""'B3L'"", ""'CK7'"", ""'MEA'"", ""'NH2'""]",CK7,316.0
169,2wfy,"truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design",2009-06-09,3,A,2.53,298.0,98.99328859060402,1.0,[3],"[[296, 298]]",3.0,"[""'ACE'"", ""'B3L'"", ""'NH2'""]",,
170,2whb,"truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design",2009-06-09,3,A,2.9,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",3.0,"[""'L3O'"", ""'NH2'"", ""'PFF'""]",,
171,2wih,structure of cdk2-cyclin a with pha-848125,2009-07-28,2,A,2.5,298.0,101.34228187919464,0.0,[],[],2.0,"[""'P48'"", ""'SO4'""]",P48,428.0
172,2wip,"structure of cdk2-cyclin a complexed with 8-anilino-1-methyl-4,5-dihydro- 1h-pyrazolo[4,3-h] quinazoline-3-carboxylic acid",2009-07-28,2,A,2.8,298.0,99.66442953020132,1.0,[1],"[[15, 15]]",2.0,"[""'P49'"", ""'SO4'""]",P49,306.0
173,2wma,structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a,2010-09-01,3,A,2.8,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",1.0,"[""'TPO'""]",,
174,2wmb,structural and thermodynamic consequences of cyclization of peptide ligands for the recruitment site of cyclin a,2010-09-01,3,A,2.6,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",2.0,"[""'MG'"", ""'TPO'""]",,
175,2wpa,"optimisation of 6,6-dimethyl pyrrolo 3,4-c pyrazoles: identification of pha-793887, a potent cdk inhibitor suitable for intravenous dosing",2010-02-23,2,A,2.51,298.0,101.34228187919464,0.0,[],[],2.0,"[""'889'"", ""'SO4'""]",889,330.0
176,2wxv,"structure of cdk2-cyclin a with a pyrazolo(4,3-h) quinazoline-3- carboxamide inhibitor",2010-02-23,2,A,2.6,298.0,101.34228187919464,0.0,[],[],2.0,"[""'SO4'"", ""'WXV'""]",WXV,394.0
177,2x1n,"truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure guided design",2010-02-16,3,A,2.75,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",4.0,"[""'ACE'"", ""'NH2'"", ""'PFF'"", ""'X1N'""]",X1N,326.0
178,2xmy,discovery and characterisation of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional cdk inhibitors as anticancer agents,2010-11-10,1,A,1.9,298.0,98.99328859060402,1.0,[3],"[[40, 42]]",1.0,"[""'CDK'""]",CDK,414.0
179,2xnb,discovery and characterisation of 2-anilino-4-(thiazol-5-yl) pyrimidine transcriptional cdk inhibitors as anticancer agents,2010-11-10,1,A,1.85,298.0,99.32885906040268,1.0,[2],"[[39, 40]]",1.0,"[""'Y8L'""]",Y8L,360.0
180,3bht,structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor meriolin 3,2008-02-12,2,A,2.0,297.0,100.0,1.0,[2],"[[41, 42]]",4.0,"[""'MFR'"", ""'MG'"", ""'SGM'"", ""'TPO'""]",MFR,230.0
181,3bhu,structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor meriolin 5,2008-02-12,2,A,2.3,297.0,100.0,1.0,[2],"[[41, 42]]",3.0,"[""'MG'"", ""'MHR'"", ""'TPO'""]",MHR,254.0
182,3bhv,structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor variolin b,2008-02-12,2,A,2.1,297.0,100.0,1.0,[2],"[[41, 42]]",4.0,"[""'MG'"", ""'SGM'"", ""'TPO'"", ""'VAR'""]",VAR,282.0
183,3ddp,structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor cr8,2008-07-22,2,A,2.7,297.0,100.0,1.0,[1],"[[299, 299]]",2.0,"[""'RC8'"", ""'TPO'""]",RC8,402.0
184,3ddq,structure of phosphorylated thr160 cdk2/cyclin a in complex with the inhibitor roscovitine,2008-07-22,2,A,1.8,297.0,99.66442953020132,1.0,[2],"[[40, 41]]",3.0,"[""'RRC'"", ""'SGM'"", ""'TPO'""]",RRC,328.0
185,3dog,structure of thr 160 phosphorylated cdk2/cyclin a in complex with the inhibitor n-&-n1,2008-09-30,2,A,2.7,297.0,100.0,1.0,[1],"[[39, 39]]",3.0,"[""'NNN'"", ""'SGM'"", ""'TPO'""]",NNN,328.0
186,3eid,cdk2/cyclina complexed with a pyrazolopyridazine inhibitor,2008-10-21,2,A,3.15,298.0,97.98657718120806,3.0,"[3, 2, 1]","[[38, 40], [161, 162], [298, 298]]",1.0,"[""'PO5'""]",PO5,460.0
187,3ej1,cdk2/cyclina complexed with a pyrazolopyridazine inhibitor,2008-10-21,2,A,3.22,298.0,98.99328859060402,1.0,[3],"[[38, 40]]",1.0,"[""'5BP'""]",5BP,240.0
188,3eoc,cdk2/cyclina complexed with a imidazo triazin-2-amine,2008-11-04,2,A,3.2,298.0,98.99328859060402,1.0,[3],"[[38, 40]]",1.0,"[""'T2A'""]",T2A,370.0
189,3ezr,cdk-2 with indazole inhibitor 17 bound at its active site,2009-02-03,1,A,1.9,298.0,91.61073825503357,2.0,"[7, 18]","[[37, 43], [147, 164]]",1.0,"[""'EZR'""]",EZR,426.0
190,3ezv,cdk-2 with indazole inhibitor 9 bound at its active site,2009-02-03,1,A,1.99,298.0,92.95302013422821,2.0,"[7, 14]","[[37, 43], [149, 162]]",1.0,"[""'EZV'""]",EZV,398.0
191,3f5x,cdk-2-cyclin complex with indazole inhibitor 9 bound at its active site,2009-02-03,2,A,2.4,298.0,99.66442953020132,1.0,[1],"[[272, 272]]",3.0,"[""'EZV'"", ""'GOL'"", ""'SO4'""]",EZV,398.0
192,3fz1,crystal structure of a benzthiophene inhibitor bound to human cyclin-dependent kinase-2 (cdk-2),2009-04-07,1,A,1.9,298.0,95.30201342281879,2.0,"[7, 7]","[[37, 43], [154, 160]]",1.0,"[""'B98'""]",B98,262.0
193,3ig7,novel cdk-5 inhibitors - crystal structure of inhibitor efp with cdk-2,2009-09-08,1,A,1.8,298.0,93.28859060402685,2.0,"[8, 12]","[[36, 43], [153, 164]]",2.0,"[""'ACE'"", ""'EFP'""]",EFP,320.0
194,3igg,novel cdk-5 inhibitors - crystal structure of inhibitor efq with cdk-2,2009-09-08,1,A,1.8,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",2.0,"[""'ACE'"", ""'EFQ'""]",EFQ,282.0
195,3le6,the structure of cyclin dependent kinase 2 (ckd2) with a pyrazolobenzodiazepine inhibitor,2010-11-17,1,A,2.0,298.0,94.96644295302013,3.0,"[9, 2, 4]","[[36, 44], [73, 74], [295, 298]]",1.0,"[""'2BZ'""]",2BZ,306.0
196,3lfn,"crystal structure of cdk2 with sar57, an aminoindazole type inhibitor",2010-03-02,1,A,2.28,298.0,95.63758389261746,2.0,"[4, 9]","[[37, 40], [152, 160]]",1.0,"[""'A27'""]",A27,350.0
197,3lfq,"crystal structure of cdk2 with sar60, an aminoindazole type inhibitor",2010-03-02,1,A,2.03,298.0,96.97986577181207,1.0,[9],"[[37, 45]]",1.0,"[""'A28'""]",A28,262.0
198,3lfs,"crystal structure of cdk2 with sar37, an aminoindazole type inhibitor",2010-03-02,1,A,2.4,298.0,97.31543624161074,1.0,[8],"[[37, 44]]",1.0,"[""'A07'""]",A07,262.0
199,3my5,cdk2/cyclina in complex with drb,2010-09-29,2,A,2.1,297.0,99.66442953020132,1.0,[3],"[[40, 42]]",4.0,"[""'FMT'"", ""'RFZ'"", ""'SGM'"", ""'TPO'""]",RFZ,236.0
200,3ns9,crystal structure of cdk2 in complex with inhibitor bs-194,2010-12-08,1,A,1.78,298.0,96.97986577181207,2.0,"[2, 7]","[[1, 2], [36, 42]]",1.0,"[""'NS9'""]",NS9,358.0
201,3pj8,"structure of cdk2 in complex with a pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine.",2011-04-06,1,A,1.96,298.0,96.64429530201343,2.0,"[3, 8]","[[38, 40], [156, 163]]",1.0,"[""'404'""]",404,328.0
202,3pxf,cdk2 in complex with two molecules of 8-anilino-1-naphthalene sulfonate,2011-02-16,1,A,1.8,298.0,101.34228187919464,0.0,[],[],2.0,"[""'2AN'"", ""'EDO'""]",2AN,286.0
203,3pxq,cdk2 in complex with 3 molecules of 8-anilino-1-naphthalene sulfonate,2011-02-16,1,A,1.9,298.0,100.0,1.0,[4],"[[41, 44]]",2.0,"[""'2AN'"", ""'EDO'""]",2AN,286.0
204,3pxr,apo cdk2 crystallized from jeffamine,2011-02-16,1,A,2.0,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'EDO'""]",,
205,3pxy,cdk2 in complex with inhibitor jws648,2011-02-16,1,A,1.8,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'JWS'"", ""'PO4'""]",JWS,222.0
206,3pxz,cdk2 ternary complex with jws648 and ans,2011-02-16,1,A,1.7,298.0,101.34228187919464,0.0,[],[],2.0,"[""'2AN'"", ""'JWS'""]",2AN,286.0
207,3py0,cdk2 in complex with inhibitor su9516,2011-02-16,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",3.0,"[""'EDO'"", ""'PO4'"", ""'SU9'""]",SU9,230.0
208,3py1,cdk2 ternary complex with su9516 and ans,2011-02-16,1,A,2.05,298.0,101.34228187919464,0.0,[],[],3.0,"[""'2AN'"", ""'EDO'"", ""'SU9'""]",2AN,286.0
209,3qhr,structure of a pcdk2/cyclina transition-state mimic,2011-05-25,3,A,2.17,295.0,100.0,1.0,[2],"[[298, 299]]",6.0,"[""'ADP'"", ""'CL'"", ""'GOL'"", ""'MG'"", ""'MGF'"", ""'TPO'""]",ADP,350.0
210,3qhw,structure of a pcdk2/cyclina transition-state mimic,2011-05-25,3,A,1.91,295.0,100.0,1.0,[2],"[[298, 299]]",6.0,"[""'ADP'"", ""'CL'"", ""'DTU'"", ""'MG'"", ""'MGF'"", ""'TPO'""]",ADP,350.0
211,3ql8,cdk2 in complex with inhibitor jws-6-260,2012-08-08,1,A,1.9,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X01'""]",X01,206.0
212,3qqf,cdk2 in complex with inhibitor l1,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X07'""]",X07,260.0
213,3qqg,cdk2 in complex with inhibitor l2-5,2012-08-08,1,A,1.9,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",3.0,"[""'EDO'"", ""'PO4'"", ""'X06'""]",X06,194.0
214,3qqh,cdk2 in complex with inhibitor l2-2,2012-08-08,1,A,1.87,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",3.0,"[""'EDO'"", ""'PO4'"", ""'X0A'""]",X0A,266.0
215,3qqj,cdk2 in complex with inhibitor l2,2012-08-08,1,A,1.7,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",3.0,"[""'EDO'"", ""'PO4'"", ""'X11'""]",X11,194.0
216,3qqk,cdk2 in complex with inhibitor l4,2012-10-31,1,A,1.86,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X02'""]",X02,246.0
217,3qql,cdk2 in complex with inhibitor l3,2012-08-08,1,A,1.85,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'X03'""]",X03,228.0
218,3qrt,cdk2 in complex with inhibitor nsk-mc2-55,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X14'""]",X14,376.0
219,3qru,cdk2 in complex with inhibitor nsk-mc1-12,2012-08-08,1,A,1.95,298.0,98.99328859060402,1.0,[3],"[[38, 40]]",2.0,"[""'EDO'"", ""'X19'""]",X19,226.0
220,3qtq,cdk2 in complex with inhibitor rc-1-137,2012-10-31,1,A,1.8,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X35'""]",X35,248.0
221,3qtr,cdk2 in complex with inhibitor rc-1-148,2012-10-31,1,A,1.85,298.0,94.6308724832215,2.0,"[8, 8]","[[37, 44], [155, 162]]",1.0,"[""'X36'""]",X36,282.0
222,3qts,cdk2 in complex with inhibitor rc-2-12,2012-10-31,1,A,1.9,298.0,94.6308724832215,2.0,"[8, 8]","[[37, 44], [155, 162]]",1.0,"[""'X46'""]",X46,310.0
223,3qtu,cdk2 in complex with inhibitor rc-2-132,2012-10-31,1,A,1.82,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'X44'""]",X44,438.0
224,3qtw,cdk2 in complex with inhibitor rc-2-13,2012-10-31,1,A,1.85,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X3A'""]",X3A,284.0
225,3qtx,cdk2 in complex with inhibitor rc-2-35,2012-10-31,1,A,1.95,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'X43'""]",X43,406.0
226,3qtz,cdk2 in complex with inhibitor rc-2-36,2012-10-31,1,A,2.0,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X42'""]",X42,360.0
227,3qu0,cdk2 in complex with inhibitor rc-2-38,2012-10-31,1,A,1.95,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X40'""]",X40,362.0
228,3qwj,cdk2 in complex with inhibitor kvr-1-142,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X6A'""]",X6A,276.0
229,3qwk,cdk2 in complex with inhibitor kvr-1-150,2012-08-08,1,A,1.85,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X62'""]",X62,262.0
230,3qx2,cdk2 in complex with inhibitor kvr-1-190,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X63'""]",X63,330.0
231,3qx4,cdk2 in complex with inhibitor kvr-1-78,2012-08-08,1,A,1.92,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X4B'""]",X4B,260.0
232,3qxo,cdk2 in complex with inhibitor kvr-1-84,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X65'""]",X65,336.0
233,3qxp,cdk2 in complex with inhibitor rc-3-89,2012-10-31,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X64'""]",X64,406.0
234,3qzf,cdk2 in complex with inhibitor jws-6-52,2012-08-08,1,A,2.0,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'X66'""]",X66,210.0
235,3qzg,cdk2 in complex with inhibitor jws-6-76,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X67'""]",X67,194.0
236,3qzh,cdk2 in complex with inhibitor kvr-1-124,2012-08-08,1,A,1.95,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X69'""]",X69,288.0
237,3qzi,cdk2 in complex with inhibitor kvr-1-126,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X72'""]",X72,262.0
238,3r1q,cdk2 in complex with inhibitor kvr-1-102,2012-08-08,1,A,1.85,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X75'""]",X75,260.0
239,3r1s,cdk2 in complex with inhibitor kvr-1-127,2012-08-08,1,A,1.8,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X73'""]",X73,260.0
240,3r1y,cdk2 in complex with inhibitor kvr-1-134,2012-08-08,1,A,1.8,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X76'""]",X76,214.0
241,3r28,cdk2 in complex with inhibitor kvr-1-140,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'XA0'""]",XA0,258.0
242,3r6x,cdk2 in complex with inhibitor kvr-1-158,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X84'""]",X84,326.0
243,3r71,cdk2 in complex with inhibitor kvr-1-162,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X86'""]",X86,338.0
244,3r73,cdk2 in complex with inhibitor kvr-1-164,2012-08-08,1,A,1.7,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X87'""]",X87,324.0
245,3r7e,cdk2 in complex with inhibitor kvr-1-67,2012-08-08,1,A,1.9,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X88'""]",X88,262.0
246,3r7i,cdk2 in complex with inhibitor kvr-1-74,2012-08-08,1,A,1.85,298.0,94.6308724832215,2.0,"[8, 8]","[[37, 44], [155, 162]]",2.0,"[""'EDO'"", ""'X9I'""]",X9I,302.0
247,3r7u,cdk2 in complex with inhibitor kvr-1-75,2012-08-08,1,A,1.75,298.0,94.6308724832215,2.0,"[8, 8]","[[37, 44], [155, 162]]",2.0,"[""'EDO'"", ""'X96'""]",X96,284.0
248,3r7v,cdk2 in complex with inhibitor kvr-1-9,2012-08-08,1,A,1.95,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'Z02'""]",Z02,260.0
249,3r7y,cdk2 in complex with inhibitor kvr-2-88,2012-08-08,1,A,1.9,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'Z04'""]",Z04,354.0
250,3r83,cdk2 in complex with inhibitor kvr-2-92,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'Z14'""]",Z14,364.0
251,3r8l,cdk2 in complex with inhibitor l3-4,2012-08-08,1,A,1.9,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'Z30'""]",Z30,216.0
252,3r8m,cdk2 in complex with inhibitor l3-3,2012-08-08,1,A,1.8,298.0,95.9731543624161,2.0,"[4, 8]","[[37, 40], [154, 161]]",2.0,"[""'PO4'"", ""'Z19'""]",Z19,168.0
253,3r8p,cdk2 in complex with inhibitor nsk-mc1-6,2012-08-08,1,A,1.8,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'Z46'""]",Z46,204.0
254,3r8u,cdk2 in complex with inhibitor rc-1-132,2012-10-31,1,A,2.0,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'Z31'""]",Z31,294.0
255,3r8v,cdk2 in complex with inhibitor rc-1-135,2012-10-31,1,A,1.9,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'Z62'""]",Z62,292.0
256,3r8z,cdk2 in complex with inhibitor rc-1-136,2012-10-31,1,A,1.85,298.0,97.31543624161074,2.0,"[4, 4]","[[37, 40], [156, 159]]",1.0,"[""'Z63'""]",Z63,248.0
257,3r9d,cdk2 in complex with inhibitor rc-2-135,2012-10-31,1,A,1.95,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'X6B'""]",X6B,374.0
258,3r9h,cdk2 in complex with inhibitor rc-2-142,2012-10-31,1,A,2.1,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'Z67'""]",Z67,374.0
259,3r9n,cdk2 in complex with inhibitor rc-2-21,2012-10-31,1,A,1.75,298.0,94.6308724832215,2.0,"[8, 8]","[[37, 44], [155, 162]]",1.0,"[""'Z68'""]",Z68,328.0
260,3r9o,cdk2 in complex with inhibitor rc-2-143,2012-10-31,1,A,1.9,298.0,94.6308724832215,2.0,"[8, 8]","[[37, 44], [155, 162]]",1.0,"[""'Z71'""]",Z71,374.0
261,3rah,cdk2 in complex with inhibitor rc-2-22,2012-10-31,1,A,1.75,298.0,94.6308724832215,2.0,"[8, 8]","[[37, 44], [155, 162]]",1.0,"[""'O1Z'""]",O1Z,330.0
262,3rai,cdk2 in complex with inhibitor kvr-1-160,2012-08-08,1,A,1.7,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'EDO'"", ""'X85'""]",X85,388.0
263,3rak,cdk2 in complex with inhibitor rc-2-32,2012-10-31,1,A,1.75,298.0,92.95302013422821,2.0,"[8, 13]","[[37, 44], [150, 162]]",1.0,"[""'03Z'""]",03Z,360.0
264,3ral,cdk2 in complex with inhibitor rc-2-34,2012-10-31,1,A,1.75,298.0,92.95302013422821,2.0,"[8, 13]","[[37, 44], [150, 162]]",1.0,"[""'04Z'""]",04Z,388.0
265,3rjc,cdk2 in complex with inhibitor l4-12,2012-10-31,1,A,1.85,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'06Z'""]",06Z,282.0
266,3rk5,cdk2 in complex with inhibitor rc-2-72,2012-10-31,1,A,2.0,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'07Z'""]",07Z,328.0
267,3rk7,cdk2 in complex with inhibitor rc-2-71,2012-10-31,1,A,1.8,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'08Z'"", ""'EDO'""]",08Z,326.0
268,3rk9,cdk2 in complex with inhibitor rc-2-74,2012-10-31,1,A,1.85,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'09Z'""]",09Z,248.0
269,3rkb,cdk2 in complex with inhibitor rc-2-73,2012-10-31,1,A,2.0,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'12Z'"", ""'EDO'""]",12Z,284.0
270,3rm6,cdk2 in complex with inhibitor kvr-2-80,2012-08-08,1,A,1.6,298.0,98.3221476510067,2.0,"[1, 4]","[[15, 15], [37, 40]]",2.0,"[""'18Z'"", ""'EDO'""]",18Z,390.0
271,3rm7,cdk2 in complex with inhibitor kvr-1-91,2012-08-08,1,A,1.85,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'19Z'"", ""'EDO'""]",19Z,274.0
272,3rmf,cdk2 in complex with inhibitor rc-2-33,2012-10-31,1,A,1.75,298.0,93.28859060402685,2.0,"[7, 13]","[[38, 44], [150, 162]]",1.0,"[""'20Z'""]",20Z,408.0
273,3rni,cdk2 in complex with inhibitor rc-3-86,2012-10-31,1,A,1.95,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'21Z'""]",21Z,360.0
274,3roy,cdk2 in complex with inhibitor kvr-1-154,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'22Z'"", ""'EDO'""]",22Z,346.0
275,3rpo,cdk2 in complex with inhibitor kvr-1-156,2012-08-08,1,A,1.75,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'24Z'"", ""'EDO'""]",24Z,354.0
276,3rpr,cdk2 in complex with inhibitor rc-2-49,2012-10-31,1,A,1.75,298.0,94.6308724832215,2.0,"[8, 8]","[[37, 44], [155, 162]]",1.0,"[""'25Z'""]",25Z,294.0
277,3rpv,cdk2 in complex with inhibitor rc-2-88,2012-10-31,1,A,1.8,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'26Z'"", ""'EDO'""]",26Z,374.0
278,3rpy,cdk2 in complex with inhibitor rc-2-40,2012-10-31,1,A,1.9,298.0,92.95302013422821,2.0,"[8, 13]","[[37, 44], [150, 162]]",1.0,"[""'27Z'""]",27Z,302.0
279,3rzb,cdk2 in complex with inhibitor rc-2-23,2012-10-31,1,A,1.9,298.0,94.6308724832215,2.0,"[8, 8]","[[37, 44], [155, 162]]",1.0,"[""'02Z'""]",02Z,224.0
280,3s00,cdk2 in complex with inhibitor l4-14,2012-10-31,1,A,1.8,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'Z60'""]",Z60,254.0
281,3s0o,cdk2 in complex with inhibitor rc-1-138,2012-10-31,1,A,2.0,298.0,98.3221476510067,2.0,"[3, 2]","[[38, 40], [147, 148]]",1.0,"[""'50Z'""]",50Z,248.0
282,3s1h,cdk2 in complex with inhibitor rc-2-39,2012-10-31,1,A,1.75,298.0,92.95302013422821,2.0,"[8, 13]","[[37, 44], [150, 162]]",1.0,"[""'56Z'""]",56Z,388.0
283,3s2p,crystal structure of cdk2 with a 2-aminopyrimidine compound,2011-07-20,1,A,2.3,298.0,93.62416107382549,2.0,"[8, 11]","[[36, 43], [153, 163]]",1.0,"[""'PMU'""]",PMU,308.0
284,3sqq,cdk2 in complex with inhibitor rc-3-96,2012-10-31,1,A,1.85,298.0,96.64429530201343,2.0,"[4, 6]","[[37, 40], [151, 156]]",2.0,"[""'99Z'"", ""'EDO'""]",99Z,372.0
285,3sw4,crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor,2012-08-01,1,A,1.7,298.0,93.62416107382549,2.0,"[9, 10]","[[36, 44], [154, 163]]",3.0,"[""'18K'"", ""'ACE'"", ""'ACT'""]",18K,308.0
286,3sw7,crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor,2012-08-01,1,A,1.8,298.0,93.28859060402685,2.0,"[7, 13]","[[38, 44], [150, 162]]",2.0,"[""'19K'"", ""'ACE'""]",19K,352.0
287,3ti1,cdk2 in complex with sunitinib,2012-08-22,1,A,1.99,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'B49'"", ""'EDO'""]",B49,352.0
288,3tiy,cdk2 in complex with nsc 35676,2012-08-22,1,A,1.84,298.0,98.3221476510067,2.0,"[1, 4]","[[1, 1], [37, 40]]",2.0,"[""'EDO'"", ""'TIY'""]",TIY,212.0
289,3tiz,cdk2 in complex with nsc 111848,2012-08-22,1,A,2.02,298.0,98.3221476510067,2.0,"[1, 4]","[[1, 1], [37, 40]]",2.0,"[""'3TI'"", ""'EDO'""]",3TI,250.0
290,3tnw,structure of cdk2/cyclin a in complex with can508,2012-02-15,2,A,2.0,297.0,99.32885906040268,1.0,[3],"[[39, 41]]",3.0,"[""'F18'"", ""'NA'"", ""'TPO'""]",F18,208.0
291,3uli,human cyclin dependent kinase 2 (cdk2) bound to azabenzimidazole derivative,2013-08-14,1,A,2.0,298.0,95.9731543624161,2.0,"[5, 7]","[[39, 43], [155, 161]]",1.0,"[""'1N3'""]",1N3,368.0
292,3unj,cdk2 in complex with inhibitor yl1-038-31,2012-01-25,1,A,1.9,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'0BX'"", ""'PO4'""]",0BX,292.0
293,3unk,cdk2 in complex with inhibitor yl5-083,2012-01-25,1,A,2.1,298.0,98.99328859060402,1.0,[3],"[[37, 39]]",2.0,"[""'0BY'"", ""'PO4'""]",0BY,292.0
294,3wbl,crystal structure of cdk2 in complex with pyrazolopyrimidine inhibitor,2013-10-30,1,A,2.0,298.0,94.96644295302013,3.0,"[1, 5, 9]","[[25, 25], [38, 42], [154, 162]]",2.0,"[""'ACT'"", ""'PDY'""]",PDY,340.0
295,4acm,cdk2 in complex with 3-amino-6-(4-{[2-(dimethylamino)ethyl]sulfamoyl}-phenyl)-n-pyridin-3-ylpyrazine-2-carboxamide,2012-05-16,1,A,1.63,298.0,92.95302013422821,3.0,"[7, 2, 12]","[[37, 43], [73, 74], [151, 162]]",3.0,"[""'7YG'"", ""'ACE'"", ""'GOL'""]",7YG,441.0
296,4bck,structure of cdk2 in complex with cyclin a and a 2-amino-4-heteroaryl- pyrimidine inhibitor,2013-03-06,2,A,2.05,297.0,100.33557046979868,1.0,[1],"[[300, 300]]",3.0,"[""'SGM'"", ""'T3E'"", ""'TPO'""]",T3E,401.0
297,4bcm,structure of cdk2 in complex with cyclin a and a 2-amino-4-heteroaryl- pyrimidine inhibitor,2013-03-06,3,A,2.45,297.0,99.32885906040268,2.0,"[3, 2]","[[41, 43], [299, 300]]",3.0,"[""'SGM'"", ""'T7Z'"", ""'TPO'""]",T7Z,462.0
298,4bcn,structure of cdk2 in complex with cyclin a and a 2-amino-4-heteroaryl- pyrimidine inhibitor,2013-03-06,3,A,2.1,297.0,99.66442953020132,1.0,[2],"[[40, 41]]",3.0,"[""'SO4'"", ""'T9N'"", ""'TPO'""]",T9N,324.0
299,4bco,structure of cdk2 in complex with cyclin a and a 2-amino-4-heteroaryl- pyrimidine inhibitor,2013-01-09,2,A,2.05,297.0,100.33557046979868,0.0,[],[],4.0,"[""'SGM'"", ""'SO4'"", ""'T6Q'"", ""'TPO'""]",T6Q,436.0
300,4bcp,structure of cdk2 in complex with cyclin a and a 2-amino-4-heteroaryl- pyrimidine inhibitor,2013-04-17,2,A,2.26,297.0,100.33557046979868,0.0,[],[],4.0,"[""'SGM'"", ""'SO4'"", ""'T3C'"", ""'TPO'""]",T3C,396.0
301,4bcq,structure of cdk2 in complex with cyclin a and a 2-amino-4-heteroaryl- pyrimidine inhibitor,2013-01-09,3,A,2.4,297.0,98.3221476510067,2.0,"[2, 3]","[[10, 11], [296, 298]]",2.0,"[""'TJF'"", ""'TPO'""]",TJF,414.0
302,4bgh,crystal structure of cdk2 in complex with pan-cdk inhibitor,2013-09-04,1,A,1.95,298.0,92.28187919463085,2.0,"[9, 14]","[[36, 44], [150, 163]]",1.0,"[""'3I6'""]",3I6,306.0
303,4bzd,structure of cdk2 in complex with a benzimidazopyrimidine,2014-08-13,1,A,1.83,298.0,92.95302013422821,3.0,"[1, 6, 14]","[[14, 14], [38, 43], [149, 162]]",3.0,"[""'ACE'"", ""'ACT'"", ""'D6I'""]",D6I,366.0
304,4cfm,structure-based design of c8-substituted o6-cyclohexylmethoxyguanine cdk1 and 2 inhibitors.,2014-12-10,2,A,2.85,297.0,99.66442953020132,1.0,[2],"[[297, 298]]",2.0,"[""'4QE'"", ""'TPO'""]",4QE,314.0
305,4cfn,structure-based design of c8-substituted o6-cyclohexylmethoxyguanine cdk1 and 2 inhibitors.,2013-12-18,2,A,2.2,297.0,99.66442953020132,2.0,"[3, 1]","[[41, 43], [301, 301]]",3.0,"[""'DTT'"", ""'JYM'"", ""'TPO'""]",JYM,242.0
306,4cfu,structure-based design of c8-substituted o6-cyclohexylmethoxyguanine cdk1 and 2 inhibitors.,2014-12-10,3,A,2.2,297.0,100.67114093959732,1.0,[2],"[[43, 44]]",3.0,"[""'2WC'"", ""'MG'"", ""'TPO'""]",2WC,358.0
307,4cfv,structure-based design of c8-substituted o6-cyclohexylmethoxyguanine cdk1 and 2 inhibitors.,2014-12-10,2,A,2.0,297.0,101.00671140939596,0.0,[],[],3.0,"[""'75X'"", ""'MG'"", ""'TPO'""]",75X,330.0
308,4cfw,structure-based design of c8-substituted o6-cyclohexylmethoxyguanine cdk1 and 2 inhibitors.,2013-12-18,2,A,2.45,297.0,100.67114093959732,0.0,[],[],2.0,"[""'SQ9'"", ""'TPO'""]",SQ9,392.0
309,4cfx,structure-based design of c8-substituted o6-cyclohexylmethoxyguanine cdk1 and 2 inhibitors.,2014-12-10,2,A,3.5,297.0,100.33557046979868,0.0,[],[],2.0,"[""'G6T'"", ""'TPO'""]",G6T,380.0
310,4d1x,cdk2 in complex with luciferin,2015-03-18,1,A,2.1,298.0,91.9463087248322,3.0,"[2, 11, 11]","[[1, 2], [36, 46], [154, 164]]",1.0,"[""'ESJ'""]",ESJ,272.0
311,4d1z,cdk2 in complex with a luciferin derivate,2015-03-18,1,A,1.85,298.0,86.57718120805369,5.0,"[6, 12, 2, 17, 3]","[[1, 6], [36, 47], [73, 74], [148, 164], [296, 298]]",1.0,"[""'WG8'""]",WG8,273.0
312,4ek3,crystal structure of apo cdk2,2013-05-01,1,A,1.34,298.0,96.30872483221478,2.0,"[9, 2]","[[36, 44], [296, 297]]",1.0,"[""'ACE'""]",,
313,4ek4,crystal structure of the cdk2 in complex with aminopyrazole inhibitor,2013-05-01,1,A,1.26,298.0,96.30872483221478,2.0,"[9, 2]","[[36, 44], [296, 297]]",3.0,"[""'1CK'"", ""'ACE'"", ""'NA'""]",1CK,190.0
314,4ek5,crystal structure of the cdk2 in complex with aminopyrazole inhibitor,2013-05-01,1,A,1.6,298.0,96.97986577181207,1.0,[9],"[[36, 44]]",2.0,"[""'03K'"", ""'ACE'""]",03K,256.0
315,4ek8,crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor,2013-05-01,1,A,1.7,298.0,93.95973154362416,2.0,"[9, 9]","[[36, 44], [153, 161]]",2.0,"[""'16K'"", ""'ACE'""]",16K,314.0
316,4eoi,"thr 160 phosphorylated cdk2 k89d, q131e - human cyclin a3 complex with the inhibitor ro3306",2013-02-06,2,A,2.0,295.0,98.99328859060402,1.0,[4],"[[39, 42]]",4.0,"[""'1RO'"", ""'DMS'"", ""'SGM'"", ""'TPO'""]",1RO,338.0
317,4eoj,"thr 160 phosphorylated cdk2 h84s, q85m, k89d - human cyclin a3 complex with atp",2013-02-06,2,A,1.65,294.0,99.32885906040268,1.0,[4],"[[40, 43]]",4.0,"[""'ATP'"", ""'MG'"", ""'SGM'"", ""'TPO'""]",ATP,398.0
318,4eok,"thr 160 phosphorylated cdk2 h84s, q85m, k89d - human cyclin a3 complex with the inhibitor nu6102",2013-02-06,2,A,2.57,293.0,98.65771812080536,2.0,"[4, 1]","[[39, 42], [299, 299]]",3.0,"[""'4SP'"", ""'SGM'"", ""'TPO'""]",4SP,380.0
319,4eol,"thr 160 phosphorylated cdk2 h84s, q85m, k89d - human cyclin a3 complex with the inhibitor ro3306",2013-02-06,2,A,2.4,293.0,98.99328859060402,3.0,"[2, 1, 1]","[[39, 40], [96, 96], [299, 299]]",4.0,"[""'1RO'"", ""'MG'"", ""'SGM'"", ""'TPO'""]",1RO,338.0
320,4eom,"thr 160 phosphorylated cdk2 h84s, q85m, q131e - human cyclin a3 complex with atp",2013-02-06,2,A,2.1,293.0,99.66442953020132,2.0,"[2, 1]","[[40, 41], [300, 300]]",3.0,"[""'ATP'"", ""'MG'"", ""'TPO'""]",ATP,402.0
321,4eon,"thr 160 phosphorylated cdk2 h84s, q85m, q131e - human cyclin a3 complex with the inhibitor ro3306",2013-02-06,2,A,2.4,294.0,100.67114093959732,0.0,[],[],3.0,"[""'1RO'"", ""'MG'"", ""'TPO'""]",1RO,338.0
322,4eoo,thr 160 phosphorylated cdk2 q131e - human cyclin a3 complex with atp,2013-02-06,2,A,2.1,295.0,98.99328859060402,2.0,"[4, 1]","[[40, 43], [300, 300]]",4.0,"[""'ATP'"", ""'MG'"", ""'SGM'"", ""'TPO'""]",ATP,398.0
323,4eop,thr 160 phosphorylated cdk2 q131e - human cyclin a3 complex with the inhibitor ro3306,2013-02-06,2,A,1.99,295.0,100.0,2.0,"[2, 1]","[[42, 43], [301, 301]]",4.0,"[""'1RO'"", ""'MG'"", ""'SGM'"", ""'TPO'""]",1RO,338.0
324,4eoq,thr 160 phosphorylated cdk2 wt - human cyclin a3 complex with atp,2013-02-06,2,A,2.15,296.0,99.32885906040268,2.0,"[3, 1]","[[40, 42], [300, 300]]",4.0,"[""'ATP'"", ""'MG'"", ""'SGM'"", ""'TPO'""]",ATP,398.0
325,4eor,thr 160 phosphorylated cdk2 wt - human cyclin a3 complex with the inhibitor nu6102,2013-02-06,2,A,2.2,296.0,98.65771812080536,2.0,"[4, 1]","[[39, 42], [299, 299]]",2.0,"[""'4SP'"", ""'TPO'""]",4SP,380.0
326,4eos,thr 160 phosphorylated cdk2 wt - human cyclin a3 complex with the inhibitor ro3306,2013-02-06,2,A,2.57,296.0,99.66442953020132,2.0,"[3, 1]","[[42, 44], [301, 301]]",2.0,"[""'1RO'"", ""'TPO'""]",1RO,338.0
327,4erw,cdk2 in complex with staurosporine,2012-08-22,1,A,2.0,297.0,97.98657718120806,2.0,"[5, 1]","[[38, 42], [177, 177]]",3.0,"[""'EDO'"", ""'OCS'"", ""'STU'""]",STU,440.0
328,4ez3,cdk2 in complex with nsc 134199,2012-08-22,1,A,2.0,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",2.0,"[""'0S0'"", ""'EDO'""]",0S0,284.0
329,4ez7,cdk2 in complex with staurosporine and 2 molecules of 8-anilino-1-naphthalene sulfonic acid,2012-08-22,1,A,2.49,298.0,101.34228187919464,0.0,[],[],3.0,"[""'2AN'"", ""'EDO'"", ""'STU'""]",STU,440.0
330,4fkg,crystal structure of the cdk2 in complex with aminopyrazole inhibitor,2013-05-08,1,A,1.51,298.0,95.9731543624161,2.0,"[9, 3]","[[36, 44], [154, 156]]",2.0,"[""'4CK'"", ""'ACE'""]",4CK,258.0
331,4fki,crystal structure of the cdk2 in complex with aminopyrazole inhibitor,2013-05-08,1,A,1.6,298.0,96.30872483221478,2.0,"[8, 3]","[[37, 44], [154, 156]]",2.0,"[""'09K'"", ""'ACE'""]",09K,254.0
332,4fkj,crystal structure of the cdk2 in complex with aminopyrazole inhibitor,2013-05-08,1,A,1.63,298.0,93.28859060402685,2.0,"[9, 11]","[[36, 44], [152, 162]]",3.0,"[""'11K'"", ""'ACE'"", ""'ACT'""]",11K,328.0
333,4fkl,crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor,2013-05-08,1,A,1.26,298.0,97.31543624161074,1.0,[8],"[[36, 43]]",2.0,"[""'ACE'"", ""'CK2'""]",CK2,196.0
334,4fko,crystal structure of the cdk2 in complex with thiazolylpyrimidine inhibitor,2013-05-08,1,A,1.55,298.0,97.6510067114094,1.0,[7],"[[38, 44]]",3.0,"[""'20K'"", ""'ACE'"", ""'ACT'""]",20K,306.0
335,4fkp,crystal structure of the cdk2 in complex with oxindole inhibitor,2013-05-08,1,A,1.6,298.0,93.62416107382549,2.0,"[9, 10]","[[36, 44], [153, 162]]",3.0,"[""'ACE'"", ""'LS5'"", ""'NA'""]",LS5,342.0
336,4fkq,crystal structure of the cdk2 in complex with oxindole inhibitor,2013-05-08,1,A,1.75,298.0,94.96644295302013,2.0,"[6, 9]","[[38, 43], [154, 162]]",3.0,"[""'42K'"", ""'ACE'"", ""'GOL'""]",42K,346.0
337,4fkr,crystal structure of the cdk2 in complex with oxindole inhibitor,2013-05-08,1,A,1.9,298.0,94.6308724832215,2.0,"[7, 9]","[[38, 44], [154, 162]]",3.0,"[""'45K'"", ""'ACE'"", ""'GOL'""]",45K,370.0
338,4fks,crystal structure of the cdk2 in complex with oxindole inhibitor,2013-05-08,1,A,1.55,298.0,92.28187919463085,3.0,"[9, 12, 2]","[[36, 44], [151, 162], [296, 297]]",2.0,"[""'46K'"", ""'ACE'""]",46K,414.0
339,4fkt,crystal structure of the cdk2 in complex with oxindole inhibitor,2013-05-08,1,A,1.6,298.0,93.28859060402685,3.0,"[9, 9, 2]","[[36, 44], [153, 161], [296, 297]]",2.0,"[""'48K'"", ""'ACE'""]",48K,386.0
340,4fku,crystal structure of the cdk2 in complex with oxindole inhibitor,2013-05-08,1,A,1.47,298.0,98.3221476510067,1.0,[5],"[[38, 42]]",3.0,"[""'60K'"", ""'ACE'"", ""'GOL'""]",60K,360.0
341,4fkv,crystal structure of the cdk2 in complex with oxindole inhibitor,2013-05-08,1,A,1.7,298.0,94.6308724832215,2.0,"[5, 11]","[[38, 42], [151, 161]]",3.0,"[""'61K'"", ""'ACE'"", ""'GOL'""]",61K,434.0
342,4fkw,crystal structure of the cdk2 in complex with oxindole inhibitor,2013-05-08,1,A,1.8,298.0,93.95973154362416,2.0,"[5, 13]","[[38, 42], [150, 162]]",3.0,"[""'62K'"", ""'ACE'"", ""'GOL'""]",62K,396.0
343,4fx3,crystal structure of the cdk2/cyclin a complex with oxindole inhibitor,2013-05-15,2,A,2.75,298.0,100.0,0.0,[],[],2.0,"[""'60K'"", ""'DTT'""]",60K,360.0
344,4gcj,cdk2 in complex with inhibitor rc-3-89,2012-10-31,1,A,1.42,298.0,102.01342281879197,0.0,[],[],2.0,"[""'EDO'"", ""'X64'""]",X64,406.0
345,4i3z,structure of pcdk2/cyclina bound to adp and 2 magnesium ions,2012-12-26,2,A,2.05,295.0,99.32885906040268,1.0,[2],"[[296, 297]]",5.0,"[""'ADP'"", ""'CL'"", ""'GOL'"", ""'MG'"", ""'TPO'""]",ADP,350.0
346,4ii5,structure of pcdk2/cyclina bound to adp and 1 magnesium ion,2013-01-23,2,A,2.15,297.0,99.32885906040268,1.0,[2],"[[296, 297]]",4.0,"[""'ADP'"", ""'GOL'"", ""'MG'"", ""'TPO'""]",ADP,350.0
347,4kd1,cdk2 in complex with dinaciclib,2013-09-18,1,A,1.7,298.0,100.0,0.0,[],[],2.0,"[""'1QK'"", ""'EDO'""]",1QK,368.0
348,4lyn,"crystal structure of cyclin-dependent kinase 2 (cdk2-wt) complex with (2s)-n-(5-(((5-tert-butyl-1,3-oxazol-2-yl)methyl)sulfanyl)-1,3-thiazol-2-yl)-2-phenylpropanamide",2013-10-02,1,A,2.0,298.0,96.30872483221478,1.0,[11],"[[153, 163]]",1.0,"[""'1YG'""]",1YG,378.0
349,4nj3,modulating the interaction between cdk2 and cyclin a with a quinoline-based inhibitor,2013-11-27,1,A,1.85,297.0,92.95302013422821,3.0,"[8, 12, 1]","[[38, 45], [150, 161], [177, 177]]",3.0,"[""'2KD'"", ""'ACE'"", ""'CSD'""]",2KD,448.0
350,4rj3,cdk2 with egfr inhibitor compound 8,2014-11-26,1,A,1.63,297.0,96.30872483221478,2.0,"[8, 3]","[[34, 41], [296, 298]]",3.0,"[""'3QS'"", ""'ACT'"", ""'ALY'""]",3QS,364.0
351,5a14,human cdk2 with type ii inhibitor,2015-07-22,1,A,2.0,298.0,95.30201342281879,3.0,"[2, 10, 2]","[[39, 40], [154, 163], [296, 297]]",2.0,"[""'ACE'"", ""'LQ5'""]",LQ5,418.0
352,5and,crystal structure of cdk2 in complex with 2-imidazol-1-yl-1h- benzimidazole processed with the crystaldirect automated mounting and cryo-cooling technology,2016-04-13,1,A,2.3,298.0,91.61073825503357,4.0,"[1, 9, 11, 4]","[[1, 1], [36, 44], [153, 163], [295, 298]]",1.0,"[""'5JE'""]",5JE,176.0
353,5ane,crystal structure of cdk2 in complex with 6-methoxy-7h-purine processed with the crystaldirect automated mounting and cryo-cooling technology,2016-04-13,1,A,1.7,298.0,98.65771812080536,1.0,[4],"[[37, 40]]",1.0,"[""'SZL'""]",SZL,144.0
354,5ani,crystal structure of cdk2 in complex with 6-chloro-7h-purine processed with the crystaldirect automated mounting and cryo-cooling technology,2016-04-13,1,A,1.9,298.0,93.95973154362416,3.0,"[1, 9, 8]","[[1, 1], [37, 45], [155, 162]]",1.0,"[""'ES4'""]",ES4,116.0
355,5anj,crystal structure of cdk2 in complex with n-(9h-purin-6-yl)thiophene- 2-carboxamide processed with the crystaldirect automated mounting and cryo-cooling technology,2016-04-13,1,A,1.6,298.0,97.6510067114094,2.0,"[2, 5]","[[1, 2], [158, 162]]",1.0,"[""'ZXC'""]",ZXC,238.0
356,5ank,"crystal structure of cdk2 in complex with 2,4,6-trioxo-1-phenyl- hexahydropyrimidine-5-carboxamide processed with the crystaldirect automated mounting and cryo-cooling technology",2016-04-13,1,A,1.9,298.0,91.61073825503357,3.0,"[9, 4, 12]","[[37, 45], [72, 75], [153, 164]]",1.0,"[""'RJI'""]",RJI,238.0
357,5ano,crystal structure of cdk2 processed with the crystaldirect automated mounting and cryo-cooling technology,2016-04-13,1,A,1.7,298.0,92.95302013422821,2.0,"[10, 11]","[[36, 45], [152, 162]]",0.0,[''],,
358,5cyi,cdk2/cyclin a covalent complex with 6-(cyclohexylmethoxy)-n-(4-(vinylsulfonyl)phenyl)-9h-purin-2-amine (nu6300),2015-09-16,2,A,2.0,297.0,100.33557046979868,0.0,[],[],2.0,"[""'55S'"", ""'TPO'""]",55S,390.0
359,5d1j,"crystal structure of cyclin-dependent kinase 2 (cdk2-wt) complex with n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl] methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (bms-387032)",2015-08-12,1,A,1.8,298.0,88.92617449664431,3.0,"[2, 14, 17]","[[13, 14], [35, 48], [147, 163]]",1.0,"[""'56H'""]",56H,356.0
360,5fp5,structure of cyclin-dependent kinase 2 with small-molecule ligand 4- fluorobenzoic acid (at222) in an alternate binding site.,2015-12-09,1,A,2.16,298.0,88.59060402684564,5.0,"[1, 11, 3, 16, 3]","[[14, 14], [36, 46], [73, 75], [149, 164], [296, 298]]",2.0,"[""'1Y6'"", ""'ACE'""]",1Y6,120.0
361,5fp6,"structure of cyclin-dependent kinase 2 with small-molecule ligand 3-(4,7-dichloro-1h-indol-3-yl)prop-2-yn-1-ol (at17833) in an alternate binding site.",2015-12-23,1,A,1.85,298.0,93.28859060402685,2.0,"[16, 4]","[[148, 163], [295, 298]]",1.0,"[""'MFZ'""]",MFZ,169.0
362,5iev,crystal structure of bay 1000394 (roniciclib) bound to cdk2,2016-04-27,1,A,2.03,298.0,95.30201342281879,2.0,"[5, 9]","[[38, 42], [154, 162]]",1.0,"[""'R0N'""]",R0N,352.0
363,5iex,"crystal structure of (r,s)-s-{4-[(5-bromo-4-{[(2r,3r)-2-hydroxy-1-methylpropyl]oxy}- pyrimidin-2-yl)amino]phenyl}-s-cyclopropylsulfoximide bound to cdk2",2016-04-27,1,A,2.03,298.0,95.63758389261746,2.0,"[5, 8]","[[38, 42], [156, 163]]",1.0,"[""'6AF'""]",6AF,340.0
364,5iey,crystal structure of a cdk inhibitor bound to cdk2,2016-04-27,1,A,1.66,298.0,95.9731543624161,2.0,"[5, 7]","[[38, 42], [155, 161]]",1.0,"[""'6AE'""]",6AE,318.0
365,5if1,crystal structure apo cdk2/cyclin a,2016-04-27,2,A,2.61,298.0,100.0,0.0,[],[],0.0,[''],,
366,5jq5,crystal structure of cdk2 in complex with inhibitor icec0942,2017-02-08,1,A,1.94,298.0,96.30872483221478,2.0,"[2, 9]","[[1, 2], [37, 45]]",2.0,"[""'ACT'"", ""'I74'""]",I74,364.0
367,5jq8,crystal structure of cdk2 in complex with inhibitor icec0943,2017-02-08,1,A,1.94,298.0,93.28859060402685,3.0,"[2, 9, 9]","[[1, 2], [36, 44], [153, 161]]",1.0,"[""'I73'""]",I73,364.0
368,5k4j,crystal structure of cdk2 in complex with compound 22,2016-07-06,1,A,1.6,298.0,94.6308724832215,2.0,"[7, 10]","[[38, 44], [153, 162]]",1.0,"[""'6QB'""]",6QB,368.0
369,5l2w,the x-ray co-crystal structure of human cdk2/cycline and dinaciclib.,2016-08-24,2,A,2.8,297.0,100.0,1.0,[1],"[[299, 299]]",3.0,"[""'1QK'"", ""'GOL'"", ""'TPO'""]",1QK,368.0
370,5lmk,structure of phopsho-cdk2-cyclin a in complex with an atp-competitive inhibitor,2017-01-25,3,A,2.4,297.0,99.66442953020132,1.0,[2],"[[40, 41]]",4.0,"[""'6ZK'"", ""'MG'"", ""'SGM'"", ""'TPO'""]",6ZK,400.0
371,5nev,cdk2/cyclin a in complex with compound 73,2017-03-29,2,A,2.97,297.0,99.32885906040268,1.0,[3],"[[297, 299]]",2.0,"[""'72L'"", ""'TPO'""]",72L,424.0
372,5oo0,cdk2(wt) covalent adduct with d28 at c177,2018-03-14,1,A,1.6,298.0,96.64429530201343,3.0,"[1, 7, 2]","[[1, 1], [37, 43], [296, 297]]",1.0,"[""'9YZ'""]",,
373,5oo1,"cdk2(f80c, c177a) covalent adduct with c37 at f80c",2018-08-29,1,A,2.0,296.0,93.28859060402685,2.0,"[3, 17]","[[1, 3], [147, 163]]",1.0,"[""'9Z2'""]",9Z2,214.0
374,5oo3,"cdk2(f80c, c177a) with covalent ligand at f80c",2018-08-29,1,A,1.73,296.0,95.9731543624161,3.0,"[1, 7, 4]","[[1, 1], [38, 44], [295, 298]]",1.0,"[""'9ZB'""]",9ZB,200.0
375,5osj,cdk2(wt) with covalent adduct at c177,2018-03-14,1,A,1.83,298.0,97.98657718120806,3.0,"[1, 3, 2]","[[1, 1], [39, 41], [296, 297]]",1.0,"[""'AAK'""]",,
376,5osm,"cdk2(f80c, c177a) with covalent adduct at c80",2018-03-14,1,A,1.77,296.0,97.98657718120806,2.0,"[8, 2]","[[41, 48], [300, 301]]",1.0,"[""'AEQ'""]",AEQ,230.0
377,5uq1,crystal structure of human cdk2-spy1 complex,2017-07-05,2,A,3.2,298.0,96.64429530201343,3.0,"[2, 6, 2]","[[1, 2], [22, 27], [296, 297]]",0.0,[''],,
378,5uq2,crystal structure of human cdk2-spy1 complex,2017-07-05,2,A,2.7,298.0,99.32885906040268,1.0,[2],"[[296, 297]]",0.0,[''],,
379,6gub,cdk2/cyclina in complex with flavopiridol,2018-12-05,2,A,2.52,297.0,98.65771812080536,2.0,"[3, 2]","[[39, 41], [297, 298]]",2.0,"[""'F9Z'"", ""'TPO'""]",F9Z,346.0
380,6guc,cdk2/cyclina in complex with su9516,2018-12-05,2,A,2.0,297.0,97.98657718120806,2.0,"[5, 2]","[[37, 41], [297, 298]]",2.0,"[""'SU9'"", ""'TPO'""]",SU9,230.0
381,6gue,cdk2/cyclina in complex with azd5438,2018-12-05,3,C,1.99,297.0,96.97986577181207,3.0,"[5, 3, 2]","[[226, 230], [243, 245], [297, 298]]",2.0,"[""'FB8'"", ""'TPO'""]",FB8,350.0
382,6guf,cdk2/cyclina in complex with cgp74514a,2018-12-05,2,A,2.65,297.0,99.32885906040268,1.0,[3],"[[39, 41]]",2.0,"[""'23D'"", ""'TPO'""]",23D,326.0
383,6guh,cdk2 in complex with azd5438,2018-12-05,1,A,1.5,298.0,95.30201342281879,2.0,"[8, 8]","[[40, 47], [151, 158]]",2.0,"[""'EDO'"", ""'FB8'""]",FB8,350.0
384,6guk,cdk2 in complex with cgp74514a,2018-12-05,1,A,1.3,298.0,93.28859060402685,2.0,"[10, 10]","[[37, 46], [154, 163]]",1.0,"[""'FC8'""]",FC8,326.0
385,6gva,"cdk2/cyclin a2 in complex with pyrazolo[4,3-d]pyrimidine inhibitor lgr4455",2019-05-01,2,A,2.15,297.0,96.64429530201343,2.0,"[2, 8]","[[39, 40], [291, 298]]",8.0,"[""'BR'"", ""'CL'"", ""'EDO'"", ""'FCQ'"", ""'PG4'"", ""'PGE'"", ""'SGM'"", ""'TPO'""]",FCQ,394.0
386,6q3b,cdk2 in complex with fraglite2,2019-03-20,1,A,1.11,298.0,94.96644295302013,2.0,"[7, 8]","[[38, 44], [155, 162]]",1.0,"[""'PYZ'""]",,
387,6q3c,cdk2 in complex with fraglite1,2019-03-20,1,A,1.29,297.0,96.64429530201343,3.0,"[1, 8, 1]","[[1, 1], [37, 44], [177, 177]]",2.0,"[""'BYZ'"", ""'OCS'""]",,
388,6q3f,cdk2 in complex with fraglite2,2019-03-20,1,A,1.18,297.0,97.98657718120806,2.0,"[9, 1]","[[40, 48], [181, 181]]",2.0,"[""'HEW'"", ""'OCS'""]",,
389,6q48,cdk2 in complex with fraglite7,2019-03-20,1,A,1.03,298.0,93.95973154362416,3.0,"[8, 8, 2]","[[38, 45], [154, 161], [296, 297]]",2.0,"[""'DMS'"", ""'HHQ'""]",HHQ,90.0
390,6q49,cdk2 in complex with fraglite6,2019-03-20,1,A,1.0,298.0,96.30872483221478,2.0,"[6, 5]","[[38, 43], [157, 161]]",2.0,"[""'DMS'"", ""'HGQ'""]",,
391,6q4a,cdk2 in complex with fraglite14,2019-03-20,1,A,1.13,298.0,97.6510067114094,2.0,"[6, 1]","[[39, 44], [126, 126]]",1.0,"[""'HGW'""]",HGW,76.0
392,6q4b,cdk2 in complex with fraglite13,2019-03-20,1,A,1.12,298.0,97.6510067114094,1.0,[7],"[[38, 44]]",1.0,"[""'HHN'""]",HHN,76.0
393,6q4c,cdk2 in complex with fraglite16,2019-03-20,1,A,1.73,298.0,98.3221476510067,1.0,[7],"[[40, 46]]",1.0,"[""'HH8'""]",HH8,124.0
394,6q4d,cdk2 in complex with fraglite31,2019-03-20,1,A,1.07,298.0,96.64429530201343,3.0,"[7, 1, 2]","[[38, 44], [177, 177], [296, 297]]",1.0,"[""'HHT'""]",HHT,156.0
395,6q4e,cdk2 in complex with fraglite33,2019-03-20,1,A,1.06,298.0,95.30201342281879,2.0,"[7, 8]","[[39, 45], [155, 162]]",2.0,"[""'DMS'"", ""'HH5'""]",HH5,130.0
396,6q4f,cdk2 in complex with fraglite32,2019-03-20,1,A,1.21,297.0,97.6510067114094,3.0,"[7, 1, 1]","[[40, 46], [126, 126], [179, 179]]",2.0,"[""'26D'"", ""'OCS'""]",26D,102.0
397,6q4g,cdk2 in complex with fraglite37,2019-03-20,1,A,0.98,297.0,94.6308724832215,2.0,"[6, 10]","[[39, 44], [154, 163]]",1.0,"[""'HJK'""]",HJK,258.0
398,6q4h,cdk2 in complex with fraglite36,2019-03-20,1,A,1.0,298.0,97.6510067114094,2.0,"[6, 2]","[[40, 45], [155, 156]]",2.0,"[""'DMS'"", ""'HGH'""]",HGH,274.0
399,6q4i,cdk2 in complex with fraglite35,2019-03-20,1,A,1.11,297.0,96.64429530201343,2.0,"[7, 3]","[[38, 44], [153, 155]]",2.0,"[""'DMS'"", ""'HGK'""]",HGK,234.0
400,6q4j,cdk2 in complex with fraglite34,2019-03-20,1,A,1.05,298.0,96.97986577181207,2.0,"[8, 2]","[[39, 46], [155, 156]]",2.0,"[""'DMS'"", ""'HHB'""]",HHB,218.0
401,6q4k,cdk2 in complex with fraglite38,2019-03-20,1,A,1.06,298.0,97.6510067114094,2.0,"[7, 1]","[[39, 45], [125, 125]]",2.0,"[""'EDO'"", ""'HHW'""]",,
